Over the past 10 years, the scientific community in the ageing research field has developed a growing interest in the mammalian sirtuin family (formed by paralogues SIRT1 to SIRT7), and more specifically in SIRT1, the closest homologue of yeast Sir2 (Ref. 1). This interest stems from pioneering reports linking Sir2 to lifespan regulation in lower organisms. In particular, the genetic overexpression of Sir2 was shown to increase lifespan in yeast 2 , worms 3 and flies 4 . This remarkable effect was further corroborated in studies using purported Sir2-chemical activators; most notably resveratrol, which extended lifespan in yeast 5 , worms and flies 6 in a Sir2-dependent manner. Moreover, calorie restriction, which is the most effective dietary intervention to extend lifespan in different organisms 1 , was shown to require Sir2 in order to produce lifespan extension in both yeast 7 and flies 4 . All these studies led to the appealing hypothesis that SIR2 is an evolutionary conserved longevity gene that mediates calorie restriction effects. If this is the case, then SIRT1 activation in mammals might improve ageing without the necessity to reduce food intake. As discussed below, recent research in genetically modified mice has demonstrated clear positive effects of SIRT1 on various aspects that are related to mammalian health, including ageing-associated diseases. However, current evidence does not support the idea that SIRT1 can increase mammalian longevity.
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Tidal changes
The story of SIRT1 has had its tidal changes, which should not be surprising when dealing with proteins that integrate and coordinate multiple stimuli and responses. Often, expectations run too high, and this is inevitably followed by counter expectations that are then too low. In the case of SIRT1, the high expectations of its role in longevity were dimmed by studies that challenged the idea that Saccharomyces cerevisiae Sir2 mediates calorie restriction-associated lifespan extension 8, 9 , and also subsequently by a report that failed to reproduce lifespan extension by resveratrol in Drosophila melanogaster and Caenorhabditis elegans 10 . In mammals, resveratrol was shown to have beneficial effects on health, including improved glucose tolerance and protection from fatty liver, but without extending lifespan [11] [12] [13] . However, accumulating evidence indicates that resveratrol is not a direct activator of SIRT1 (Refs 14-16), but rather functions indirectly through AMPactivated protein kinase (AMPK) 17, 18 (Box1).
Together, these conflicting results have cast a shadow over the relevance of SIRT1 to mammalian ageing 19 . Another aspect that has generated debate is the relationship between SIRT1 and cancer, which in turn has its roots in the interplay between SIRT1 and p53. Early studies with in vitro cultured cells showed that SIRT1 can interact with and deacetylate the tumour suppressor protein p53, therefore inhibiting its transactivation potential 20, 21 .
In support of this, studies in Sirt1-knockout mice showed p53 hyperactivation, leading to increased thymocyte apoptosis 22 , although this could not be confirmed by other investigators 23 . Moreover, SIRT1 is upregulated in several types of human tumours (reviewed in Ref. 24) , which has further supported the idea that SIRT1 could be oncogenic. However, contrary to this, all the currently available data indicate that SIRT1 is a tumour suppressor in vivo [25] [26] [27] [28] , and the possible consequences of SIRT1 on p53-mediated tumour suppression remain to be elucidated.
The above controversies highlight the importance of genetically modified mouse models for addressing the effects of SIRT1 in the context of the organism. In this Progress article, we discuss recent studies using genetic mouse models of SIRT1 that have shed new light onto the field. For more comprehensive reviews on SIRT1, see Refs 29, 30. 
SIRT1 and metabolism
The effects of SIRT1 in metabolism are the best-characterized of all its effects. A considerable amount of recent literature based on various genetically modified mouse models has solidly demonstrated a protective role for SIRT1 against pathologies that are associated with a chronic intake of a high-fat diet (HFD), such as glucose intolerance and liver steatosis (also known as fatty liver) (TABLe 1) .
The first mouse models that linked SIRT1 to improved glucose tolerance were studies in which SIRT1 overexpression was restricted, in one case, to pancreatic β-cells 31 and, in another case, to brain and adipose tissue 32 . The effect of SIRT1 on metabolism has been further explored in mice with whole-body transgenic expression of moderately increased levels of SIRT1 (twofold to threefold) under its own endogenous transcriptional regulators 33, 34 . Importantly, these Sirt1-transgenic mice were protected from diabetes that is associated with dietinduced obesity 33, 34 and genetically induced obesity 34 . The effect of moderate systemic SIRT1 overexpression on protection from high dietary fat goes beyond glucose tolerance. In fact, transgenic mice that overexpress Sirt1 in all tissues are remarkably SIRT1: recent lessons from mouse models protected from developing liver steatosis 33 . consistent with this, mice that are deficient in Dbc1, a negative regulator of SIRT1, are also protected from fatty liver 35 , and conversely Sirt1-heterozygous mice are prone to developing this disease 36 . Mice with tissue-specific deletion of Sirt1 have further refined the picture and have indicated that SIRT1 exerts its protective metabolic effects through its actions on multiple tissues. For example, myeloid lineage-specific deletion of Sirt1 resulted in insulin resistance 37 , and brain-specific Sirt1 deletion increased ageing-associated glucose intolerance 38 . The deletion of Sirt1 in pro-opiomelanocortin (POMc) neurons that control food intake and energy expenditure, resulted in leptin resistance in these neurons and increased susceptibility to diet-induced obesity 39 . Finally, liver-specific deletion of Sirt1 rendered mice susceptible to steatosis 40 . However, it should be mentioned that other investigators have reported the opposite phenotype using the same genetic model of Sirt1 deficiency in the liver 41 ; the reasons for these conflicting results are unclear. Other metabolic studies using Sirt1-null mice also produced paradoxical results. In particular, Sirt1-null mice have increased glucose tolerance 42 and protection from fatty liver that is induced by liver X receptor (lXR; also known as nR1H3) agonists 43 , which is in sharp contrast to the evidence above that indicates that increased expression of Sirt1 protects from glucose intolerance and fatty liver. However, the interpretation of the results that were obtained with Sirt1-null mice is highly complex given that most of these mice die in the perinatal period and that the survivors have developmental defects 22, 44 that might obscure the role of SIRT1 in a normal physiological context. In summary, as listed in TABLe 1, most studies using a variety of mouse models have concluded that SIRT1 is a robust metabolic protector functioning in several systems, including the liver, the brain and the immune system.
A recurrent mechanistic finding in the mouse models that link SIRT1 to protection from diabetes and fatty liver is a reduced inflammatory response that is associated with lower levels of nuclear factor-κb (nF-κb) activity These results from studies in mice fully support the earlier finding in cultured cells that SIRT1 binds, deacetylates and inhibits nF-κb 45 . Another recurrent mechanism is the deacetylation and activation of key transcription factors that are involved in lipid metabolism, such as FOXO1 (Ref. 34) and the nuclear receptors peroxisome proliferator-activated receptor-α (PPARα; also known as PPARA) 40 , lXR 43 and farnesoid X activated receptor (FXR; also known as nR1H4) 46 , as well as their general co-activator PPARγ co-activator 1α (PPARGc1A; also known as PGc1α) 33, 40, 47 (fIG. 1). numerous additional mechanisms that implicate SIRT1 in metabolism have been also reported, but their detailed discussion goes beyond the scope of this article. briefly, these additional mechanisms include increased insulin production by the repression of uncoupling protein 2 (Refs 31,42); deacetylation and inhibition of sterol-regulated element-binding transcription factor (SREbP) 33, 40, 48, 49 ; repression of the Pparg promoter 50 ; activation of the Sirt6 promoter 51 and increased SIRT6 (Ref. 51 ), which can provide protection from metabolic damage 52 ; and deacetylation and activation of lKb1 (Refs 53, 54) .
Diabetes and fatty liver are diseases that often occur concurrently, as well as in association with other pathologies, notably cardiovascular disease. This group of associated pathologies is referred to as metabolic syndrome 55 . In this regard, it is worth mentioning that there is also evidence from Sirt1 mouse models that SIRT1 can improve cardiovascular function [56] [57] [58] [59] . Metabolic syndrome frequently occurs in individuals who are chronically exposed to high calorie intake and low physical activity -a lifestyle of increasing prevalence that explains the high incidence of metabolic syndrome-associated diseases worldwide 55 .
On the basis of the data mentioned above in genetically modified mice, SIRT1 activation is an attractive target for pharmaceutical interventions that are aimed at delaying or ameliorating the pathologies that are associated with metabolic syndrome.
SIRT1 and cancer
The analysis of cancer in mice with genetically modified SIRT1 levels has consistently supported the idea that SIRT1 has strong tumour suppressive activity (TABLe 1) . In particular, increased SIRT1 expression results in delayed sarcoma and lymphoma development in p53-heterozygous mice, whereas the opposite is observed with decreased SIRT1 expression levels 27, 28 . Interestingly, both studies also obtained supporting in vitro evidence indicating that this tumour suppressive activity reflected the ability of SIRT1 to preserve genomic integrity that is caused by p53 deficiency 27, 28 . upon DnA damage, chromatin-bound SIRT1 relocates from repetitive DnA to the actual DnA-damaged sites, presumably repressing transcription 27 (fIG. 1) .
Following on from the reported functions of SIRT1 in the protection from DnA damage and in the protection from fatty liver, whole-body Sirt1-transgenic mice were subjected to a novel carcinogenic treatment that models metabolic syndromeassociated liver cancer. In particular, a chronic HFD dramatically increases the incidence of liver carcinomas in mice that were previously treated with a hepatic carcinogen (diethylnitrosamine), which on its own has poor carcinogenic activity 26, 60 . Importantly, Sirt1-transgenic mice were remarkably protected from metabolic syndrome-driven liver carcinogenesis 26 . This protection was due to the combined effects of SIRT1: first, by reducing DnA damage caused by the hepatic mutagen, and second, by preventing inflammation and fatty liver induced by the HFD 26 ( fIG. 1) . Dietary obesity leads to liver inflammation by enhancing the expression of interleukin-6 (Il-6) and tumour necrosis factor-α (TnFα), which are well-known targets of nF-κb, and this inflammation promotes tumorigenesis 60 . Sirt1-transgenic mice show decreased nF-κb activation and concomitantly decreased inflammation in the liver, which results in the observed protection from liver tumorigenesis 26, 33 . notably, human liver cancers have decreased levels of SIRT1 compared with normal liver samples 28 . It remains to be elucidated whether SIRT1
Box 1 | Resveratrol and SIRT1
Resveratrol has been widely used as a SIRT1 activator, but several studies have concluded that resveratrol is not a direct activator of SIRT1 (Refs 14-16 ). This does not invalidate the concept that resveratrol can activate SIRT1 in vivo through indirect mechanisms. In fact, reports published more than 10 years ago indicated that resveratrol was an inhibitor of mitochondrial ATP synthase 70 , and this was corroborated by the crystallographic structure of ATP synthase complexed with resveratrol 71 . Inhibition of ATP synthase is predicted to increase AMP levels and therefore activate AMP-activated protein kinase (AMPK). In fact, resveratrol has recently been demonstrated to activate AMPK 18 , which increases NAD + levels and this in turn activates SIRT1 (Ref. 17) . This chain of events provides a rationale for how resveratrol, albeit indirectly, can activate SIRT1.
protects from inflammation-associated tumorigenesis in general or only from carcinogenesis that is associated with dietary-induced inflammation.
A tumour suppressive function for SIRT1 is also evident in other mouse models. SIRT1 overexpression in enterocytes provided protection from intestinal tumours in the Apc +/min mouse model 25 . This observation led to the discovery that SIRT1 deacetylates and inhibits β-catenin in the intestine of these mice 25 ( fIG. 1) . In further support of this, subsequent studies showed that SIRT1 suppresses the growth of human colon cancer xenografts 61 
.
Of note, recent studies using Sirt1-null mice revealed no difference in tumour development when crossed with Apc +/min mice 62 . As alluded to above, caution must be taken when interpreting the pheno types observed in whole-body Sirt1-null strains owing to their developmental defects and possible compensatory adaptations 22, 44 . Finally, regarding ageing-associated spontaneous cancer, whole-body Sirt1-transgenic mice had a global decrease in cancer incidence 26 . This protection, however, was restricted to carcinomas and sarcomas, whereas lymphoma development was not affected by Sirt1 dosage. This differential effect is currently not well understood and it contrasts with the previously mentioned SIRT1-dependent protection from p53-deficient lymphomas. The ageing-associated lymphomas that develop in a p53-functional context are conceivably less aggressive and less genetically unstable than the lymphomas that develop in the absence of p53. Therefore, the ability of SIRT1 to preserve genomic stability could be less relevant to the context of ageing-associated lymphomas. SIRT1 overexpression was also found to have no effect on chemically induced fibrosarcomas 26 . Apart from these two cancer models, the general finding in the data discussed above is that SIRT1 protects from cancer through several mechanisms, including protection from DnA damage, protection from dietinduced inflammation and inhibition of the oncogenic activity of β-catenin (fIG. 1) . At present, there are no reports of mouse models of cancer in which SIRT1 has a definitive oncogenic role (TABLe 1) .
SIRT1 and ageing
The effect of SIRT1 on mammalian ageing has long been sought in the research field. Importantly, mice moderately overexpressing SIRT1 (threefold overexpression) under the transcriptional regulatory elements of Sirt1 do not live longer than wild-type mice when fed a standard diet, but they show healthier ageing 26 . In particular, aged Sirt1-transgenic mice showed improved glucose homeostasis, better preservation of bone mineralization, reduced incidence 63, 64 . The emerging picture is one in which SIRT1, through its protective activities against diet-induced metabolic damage, genomic instability and cancer, improves some aspects of ageing and delays or ameliorates several ageing-associated diseases, such as metabolic syndrome, Alzheimer's disease and some types of cancer. In summary, although current evidence does not allow us to categorize SIRT1 as a 'longevity' gene, it is clearly a beneficial gene for ageing and ageing-associated diseases.
A related issue is whether SIRT1 mediates the effects of calorie restriction on ageing. Only one report has directly addressed this by using Sirt1-null mice under calorie restriction 65 . As mentioned above, most Sirt1-null mice die in the perinatal period and those that survive have developmental defects 22, 44 , including a shortened lifespan (median lifespan of approximately 1 year) 65 . Interestingly, calorie restriction started between 5 months and 7 months of age did not have an impact on the longevity of Sirt1-null mice 65 . Although suggestive, the abnormally short lifespan of Sirt1-null mice makes it difficult to interpret their lack of response to calorie restriction. Additionally, some of the beneficial effects of SIRT1 on metabolism are also characteristically produced by calorie restriction, such as improved insulin sensitivity. Finally, several studies have reported various molecular and phenotypic effects of calorie restriction that are mediated by SIRT1 in mice 38, [65] [66] [67] [68] [69] . Overall, there is growing evidence indicating that SIRT1 participates in calorie restriction.
Conclusions and future perspectives
Recent work with genetically modified mice has firmly established SIRT1 as a protector from metabolic syndrome and as a tumour suppressor in a wide range of cancers. Moreover, emerging evidence implicates SIRT1 in protection from cardiovascular disease [56] [57] [58] [59] and neurodegeneration 63, 64 . The fact that SIRT1 impinges on such a variety of ageing-associated diseases suggests that it could be a longevity gene, although direct evidence for this is still lacking in mammals. The only available study of longevity in a mouse model with systemic SIRT1 overexpression (threefold overexpression) reported improved health during ageing, but normal longevity 26 . In this regard, it would be interesting to test whether higher levels of SIRT1 overexpression or contemporaneous overexpression of several sirtuins could extend longevity.
Regarding metabolism, it would be of crucial importance to know whether SIRT1 activation could be effective at reversing, rather than preventing, diabetes. To this end, and until potent SIRT1 activators are developed, SIRT1-inducible knock-in mice could be used to explore this possibility. If these activators show a benefit in patients with diabetes, and given the cancer protection activity of SIRT1, it is tempting to speculate that they might concomittantly diminish cancer incidence. Precedence for this can be found in the anti-diabetic drug metformin, which decreases cancer incidence in both mice 63, 64 and humans 63, 64 . with respect to cancer, genetic studies published so far support a protective role for SIRT1 in many types of cancer. However, this is not general and there are examples of mouse cancer types in which SIRT1 does not have a role (TABLe 1) . numerous studies based on in vitro cultured cancer cell lines have suggested that SIRT1 has oncogenic activities 24 . Although this has not been confirmed in a more physiological setting, it remains possible that future studies could reveal oncogenic activities of SIRT1 in vivo. Finally, a key pending question is whether activators of SIRT1 could have therapeutic activity in cancer. Figure 1 | Summary of the main mechanisms through which SIrT1 protects against metabolic damage and cancer. a | The main mechanisms by which SIRT1, through direct deacetylation, protects from metabolic damage. b | The three mechanisms reported so far that support a role in cancer protection by SIRT1 in mice. FXR, farnesoid X activated receptor (also known as NR1H4); LXR, liver X receptor (also known as NR1H3); NF-κB, nuclear factor-κB; PPARα, peroxisome proliferator-activated receptor-α (also known as PPARA); PPARgC1A, PPARγ co-activator 1α (also known as PgC1α); SREBP, sterol regulatory element-binding protein.
